Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

The following is a summary of “Prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome,” published in the January ...

The Extracorporeal Life Support Organization has documented the application of venovenous extracorporeal membrane oxygenation ...

Inhaled nitric oxide market thrives on neonatal expansions, portable system breakthroughs, and precise dosing innovations.

导读肺挫伤是指胸部创伤后对肺实质造成的直接或间接的损伤，肺挫伤后血液和其他体液在肺组织内积聚，过多的液体使通气/血流比失衡，从而导致缺氧。肺挫伤是引起急性肺损伤(acute lung injury, ALI)、急性呼吸窘迫综合征(acute ...

Medscape’s Neha Pathak, MD, and George Koob, PhD, Director of the National Institute on Alcohol Abuse and Alcoholism, break down the latest guidance on alcohol intake.